Enigmatic disorder begins to yield to research
April 1st 2004This issue of Urology Times includes a number of articles from one ofthe most successful meetings on interstitial cystitis ever held, the NationalInstitute of Diabetes, Digestive, and Kidney Disorders and InterstitialCystitis Association joint symposium "Research Insights into InterstitialCystitis" in Alexandria, VA, last fall.
DHEA may increase risk of BPH, study shows
March 31st 2004Dehydroepiandrosterone (DHEA), a popular supplement among athletes, does not increase testosterone levels and may, in fact, break down into hormones associated with prostate gland growth, according to results of a small study from the Keck School of Medicine at the University of Southern California, Los Angeles.
PCa prevention with 5-ARIs: What to tell patients
March 1st 2004A major breakthrough in the field of prostate cancer research was announced last summer. For the first time in a randomized clinical trial, a drug was found to reduce the risk of prostate cancer. Widely reported headlines such as "Drug might prevent prostate cancer, researchers say" (USA Today, June 25, 2003, page 1) were tempered by reports of the drug's "disturbing" side effects.
Therapeutic cloning is used to generate renal cells
March 1st 2004Chicago--Therapeutic cloning can be used to generate immune-compatible renal cells, according to the results of a collaborative study from the Laboratory for Tissue Engineering, Children's Hospital, Harvard Medical School, Boston, and Advanced Cell Technology, Worcester, MA. The technique may be used to engineer renal tissue for autologous applications, researchers suggest.
Men embrace PSA test, but are they overly enthusiastic?
March 1st 2004White River Junction, VT--The often-controversial PSA test has now achieved broad public acceptance as a screening tool, according to a recent study. But only a minority of primary care physicians are following published guidelines for administering the test, according to another, separate study.
Investigational PDE-5 inhibitor comparable to sildenafil, study shows
February 18th 2004A phase II study comparing the onset of action of two oral phosphodiesterase-type 5 inhibitors?TA-1790, an investigational agent and sildenafil citrate (Viagra) showed comparable results, according to VIVUS, Inc., maker of TA-1790.
In-office test found useful adjunct to cystoscopy
February 15th 2004Las Vegas--An in-office bladder cancer test is significantly more sensitive than cytology at detecting the disease in high-risk patients, report community-based urologists from Anchorage, AK. The test also appears to be effective at determining risk of recurrence in patients with known disease, at least in the short term.
Allografts vs. mesh: Experts debate their pros, cons
February 15th 2004Las Vegas--Which material is better for pelvic floor reconstruction: allografts or synthetic mesh? If you ask two of urology's leading pelvic floor surgeons, each will provide a very different answer. Gary Leach, MD, a proponent of allografts, and Shlomo Raz, MD, a proponent of synthetic slings, made their points known in a verbal face-off at the AUA Western Section annual meeting here